Literature DB >> 1678604

Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease.

J M Ordovas1, F Civeira, J Genest, S Craig, A H Robbins, T Meade, M Pocovi, P M Frossard, U Masharani, P W Wilson.   

Abstract

Data from various laboratories have indicated associations of various alleles determined by RFLPs within or adjacent to several apolipoprotein genes with abnormalities in plasma lipids and/or premature coronary artery disease (CAD). In order to assess such relationships we have examined allele frequencies of 8 different RFLPs within or adjacent to the apo A-I, C-III and A-IV gene complex on the long arm of chromosome 11 (MspI, 5' to the apo A-I gene; MspI, within the apo A-I gene; PstI, 3' to the apo A-I gene; SstI, 3' to the apo C-III gene; PvuII, within the apo C-III gene; PvuII, 5' to the apo C-III gene; XbaI, within the apo A-IV gene; and XbaI, 3' to the apo A-IV gene) in 202 patients with CAD (50% narrowing of one or more coronary arteries) prior to age 60 and 145 normal controls. None of the allele frequencies of these RFLPs were significantly different in cases as compared to controls. With regard to associations with plasma lipids and apolipoprotein levels, the rare allele determined by the absence of the PstI site was associated with elevated triglyceride levels (P less than 0.05) in cases, but not in controls. In contrast, the rate MspI allele 5' to the apo A-I gene was associated with elevated triglyceride levels (P less than 0.05) in controls but not in cases. In both cases and controls, subjects with the uncommon SstI allele had triglyceride levels that were 9 and 38% higher than in those without this allele. These differences were significant (P less than 0.05) only in controls. Our data indicate that the rare allele determined by the SstI site within this gene complex deserves further study in order to understand its association with elevated triglycerides in Caucasian populations. However, at the present time all these DNA markers lack sufficient specificity to be clinically useful for CAD risk assessment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678604     DOI: 10.1016/0021-9150(91)90234-t

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

2.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

3.  Regression-based association analysis with clustered haplotypes through use of genotypes.

Authors:  Jung-Ying Tzeng; Chih-Hao Wang; Jau-Tsuen Kao; Chuhsing Kate Hsiao
Journal:  Am J Hum Genet       Date:  2005-12-19       Impact factor: 11.025

4.  Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients.

Authors:  Tarek A Abd El-Aziz; Rasha H Mohamed; Reem M Hashem
Journal:  Mol Cell Biochem       Date:  2011-04-17       Impact factor: 3.396

Review 5.  Genetics of the Framingham Heart Study population.

Authors:  Diddahally R Govindaraju; L Adrienne Cupples; William B Kannel; Christopher J O'Donnell; Larry D Atwood; Ralph B D'Agostino; Caroline S Fox; Marty Larson; Daniel Levy; Joanne Murabito; Ramachandran S Vasan; Greta Lee Splansky; Philip A Wolf; Emelia J Benjamin
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

6.  Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels.

Authors:  J C Cohen; Z Wang; S M Grundy; M R Stoesz; R Guerra
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

7.  Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11.

Authors:  Michael Olivier; Xujing Wang; Regina Cole; Brian Gau; Jessica Kim; Edward M Rubin; Len A Pennacchio
Journal:  Genomics       Date:  2004-05       Impact factor: 5.736

8.  Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element.

Authors:  P J Gruber; A Torres-Rosado; M L Wolak; T Leff
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

9.  An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population.

Authors:  Q Zeng; M Dammerman; Y Takada; A Matsunaga; J L Breslow; J Sasaki
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

10.  An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese.

Authors:  Keisuke Shioji; Toshifumi Mannami; Yoshihiro Kokubo; Yoichi Goto; Hiroshi Nonogi; Naoharu Iwai
Journal:  J Hum Genet       Date:  2004-07-17       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.